MedTrace Logo

Empirical vs Tailored Therapy for H. Pylori Infection

NCT04006340 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2019-07-05

No results posted yet for this study

Summary

We aimed to compare the efficacy of genotypic resistance-guided tailored therapy vs empirical therapy for eradication of Helicobacter pylori (H. pylori) infection in randomized controlled trials.

Conditions

  • Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation
  • Helicobacter Pylori Infection

Interventions

COMBINATION_PRODUCT

triple therapy

esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg twice a day for 10 days

COMBINATION_PRODUCT

quadruple therapy

esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days

DIAGNOSTIC_TEST

dual-priming oligonucleotide-based multiplex (DPO)-PCR test

Resistance of clarithromycin 23S rRNA point mutation

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Soo-Jeong Cho, M.D., ph.D. · Department of Internal Medicine and Liver Research Institute,

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-04
Primary Completion
2019-08-31
Completion
2019-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04006340 on ClinicalTrials.gov